Kingdon Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Kingdon Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,600	Closed	-$29K	–	81
2018 Q4	$29K	Sell	1,600 -390,359	-100%	-$7.98M	﹤0.01%	59
2018 Q3	$11.5M	Buy	391,959 +18,971	+5%	+$734K	0.8%	48
2018 Q2	$17M	Buy	372,988 +156,964	+73%	+$7.63M	1.18%	25
2018 Q1	$11.4M	Buy	216,024 +100,182	+86%	+$5.85M	0.9%	41
2017 Q4	$7.88M	Sell	115,842 -40,120	-26%	-$2.81M	0.51%	62
2017 Q3	$12.9M	Buy	155,962 +81,081	+108%	+$6.43M	0.84%	41
2017 Q2	$7.01M	Buy	+74,881	New	+$4.58M	0.48%	62
2015 Q4	–	Sell	-20,600	Closed	-$1.89M	–	154
2015 Q3	$1.89M	Buy	+20,600	New	+$1.78M	0.09%	107

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kingdon Capital Management's CLVS Position: Q1 2019 in Review

Kingdon Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2019, closing a stake of 1,600 shares — an estimated $29K sold.

Kingdon Capital Management first reported a position in CLVS in Q3 2015 and held it in 8 quarters. The position peaked at $17M in Q2 2018. 186 funds tracked by Wall St. Rank hold CLVS as of Q1 2019.

Kingdon Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2019 after selling out during the quarter.
Kingdon Capital Management sold 1,600 Clovis Oncology, Inc. shares in Q1 2019, an estimated $29K.
Kingdon Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 8 quarters.
Kingdon Capital Management's Clovis Oncology, Inc. position peaked at $17M in Q2 2018.
186 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2019.

Based on Kingdon Capital Management's 13F filing for Q1 2019, filed 14 May 2019.